Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock

On March 19, Truist began sum of Altimmune Inc. (NASDAQ:ALT) with a $12 terms target, starring to a whopping 315% upside imaginable astatine the prevailing level. The steadfast besides assigned a Buy standing to the stock.

Pressmaster/Shutterstock.com

According to Truist, Altimmune’s superior merchandise pemividutide whitethorn person a accidental to win successful the attraction of MASH, on with liver-related disorders, specified arsenic AUD. Based connected its model, Truist estimates highest adjusted oregon unadjusted gross astatine astir $600 million-$1 cardinal with 20,000 patients receiving pemividutide treatment. This makes it 1 of the astir charismatic penny banal names with dense abbreviated involvement lately.

Back connected March 16, H.C. Wainwright besides reaffirmed its Buy standing for Altimmune Inc. (NASDAQ:ALT) portion substantially expanding its terms people from $12 to $25. The steadfast attributed this to the company’s absorption connected its upcoming MASH pivotal program, on with the important short-term gains from focused efforts to combat alcohol-related illnesses.

The steadfast is presently including the imaginable commercialized worthy of pemvidutide for addressing intoxicant usage upset and related liver diseases into its foundational fiscal models. This proactive structural alteration is powerfully backed by a increasing postulation of affirmative preclinical and objective evidence. A important unmet aesculapian request successful the manufacture is straight addressed by the encouraging liver benefits seen successful these ongoing trials.

Altimmune Inc. (NASDAQ:ALT) is focused connected the improvement of innovative peptide-based therapeutics for radical suffering from superior illnesses similar liver diseases, chronic hepatitis B, NASH, and obesity. Its superior merchandise campaigner is pemvidutide, presently successful signifier 3 of the objective trial. Additionally, it has completed the MOMENTUM Phase II obesity survey and is presently being evaluated successful the IMPACT Phase IIb MASH trial.

While we admit the imaginable of ALT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.